Dr. Sébastien Fortin PhD is a regular researcher at the Centre de recherche du CHU de Québec-Laval University, Director of a pharmaceutical chemistry laboratory located at the Hôpital Saint-François d’Assise, and Associate Professor at Laval University’s School of Pharmacy. He is author and co-author of 28 publications and co-inventor of 3 patents on the technologies that he develops. Dr. Fortin is the recipient of several awards and honors, including the Jean-François St-Denis Fellowship in Cancer Research from the Canadian Institutes of Health Research (CIHR) and the 2011 award for the best doctorate in cotutelle awarded by the Ministère des Relations internationales and the Consulat général de France à Québec. His research focuses on the design and development of new anticancer agents for use in personalized medicine.

Development of new drugs for personalized cancer chemotherapy

In Canada, cancer is the leading cause of death, followed only by cardiovascular diseases. Cancer is therefore a major public health problem. Despite recent medical breakthroughs, the ability to cure all cancer patients remains elusive. Consequently, we need to develop new treatments that will be more efficient, and more selective against cancer tumors, with the aim of improving the life expectancy and the quality of life of cancer patients. The aim of my research program is to design and prepare new anticancer agents exhibiting optimal biopharmaceutical and anticancer properties suitable for preclinical and clinical studies. My research themes are divided in two parts: 1) development of new inhibitors of DNA repair and replication mechanisms and 2) development of new inhibitors targeting cells deficient in homologous recombination. My research programs involve and focus on several interrelated and complementary disciplines, including molecular design and modeling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to the development of new, efficient and personalized anticancer treatments.

Hôpital Saint-François d'Assise
10, rue de l'Espinay
D0-705C
Québec, Québec
Canada G1L 3L5
+1 418-525-2372+1 418-525-4444, extension 52364
Sebastien.Fortin@crchudeq... sebastien.fortin@pha.ulav...

Latest news

46 entries « ‹ 1 of 5 › »

Alvarez ACC, Bouzriba C, Bernier L, Ouellette V, Gagné-Boulet M, Pilote S, Gaudreault RC, Simard C, Fortin S

Development of an UHPLC-UV Method for Quantification of Three Phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates in CD-1® IGS Female Mouse Plasma

Journal Article

Journal of Analytical Chemistry, 79 (4), 2024.

Abstract | Links:

Paquin A, Nolin F, Bouzriba C, Fortin S, Sevrioukova IF, Bérubé G

Synthesis and anticancer properties of a hybrid molecule with the testosterone and estradiol head-groups

Journal Article

Steroids, 209 , 2024.

Abstract | Links:

Bouzriba C, Gagné-Boulet M, Chavez Alvarez AC, Ouellette V, Laverdière I, Fortin S

Design, synthesis and biological evaluation of new 2,6-difluorinated phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new antimicrotubule agents

Journal Article

Bioorg Chem, 146 , 2024.

Abstract | Links:

Ouellette V, Bouzriba C, Chavez Alvarez AC, Hamel-Côté G, Fortin S

Modification of the phenyl ring B of phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates by pyridinyl moiety leads to novel antimitotics targeting the colchicine-binding site

Journal Article

Bioorg Med Chem Lett, 105 , 2024.

Abstract | Links:

Ouellette V, Chavez Alvarez AC, Bouzriba C, Hamel-Côté G, Fortin S

4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamide salts: Novel hydrosoluble prodrugs of antimitotics selectively bioactivated by the cytochrome P450 1A1 in breast cancer cells

Journal Article

Bioorg Chem, 140 , 2023.

Abstract | Links:

Chavez Alvarez AC, Bouzriba C, Moreau E, Auzeloux P, Besse S, Ouellette V, Zarifi Khosroshahi M, Côté MF, Pilote S, Miot-Noirault E, Chezal JM, Simard C, C-Gaudreault R, Fortin S

Homologation of the Alkyl Side Chain of Antimitotic Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonate Prodrugs Selectively Targeting CYP1A1-Expressing Breast Cancers Improves Their Stability in Rodent Liver Microsomes

Journal Article

J Med Chem, 66 (4), 2023.

Abstract | Links:

Martin AS, Plante S, Fréchette D, Fortin S

Description des médicaments utilisés pour induire et maintenir une sédation palliative au CHU de Québec–Université Laval et à la Maison Michel-Sarrazin

Journal Article

Pharmactuel, 56 (1), 2023.

Abstract | Links:

Gagné-Boulet M, Bouzriba C, Chavez Alvarez AC, Fortin S

Rationale, synthesis and biological evaluation of substituted 1-(4-(phenylthio)phenyl)imidazolidin-2-one, urea, thiourea and amide analogs and derivatives designed to target the colchicine-binding site

Journal Article

J Mol Struct, 1259 , 2022.

| Links:

Gagné-Boulet M, Bouzriba C, Chavez Alvarez AC, Fortin S

Preparation and biological evaluation of new antimicrotubule agents: Modification of the imidazolidin-2-one moiety of phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates

Journal Article

Chem Biol Drug Des, 99 (2), 2022.

Abstract | Links:

Bouzriba C, Chavez Alvarez AC, Gagné-Boulet M, Ouellette V, Lacroix J, Côté MF, C-Gaudreault R, Fortin S

Branched alkyl of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as unique cytochrome P450 1A1-activated antimitotic prodrugs: Biological evaluation and mechanism of bioactivation

Journal Article

Eur J Med Chem, 229 , 2022.

Abstract | Links:

46 entries « ‹ 1 of 5 › »
Signaler des ajouts ou des modifications

Active projects

  • Développement et optimisation de nouveaux agents anticancéreux ciblant les cancers humains réfractaires aux traitements actuels., from 2023-07-01 to 2026-06-30
  • Eleclazine: “Boosting” efficacy and safety of the antineoplastic drug Alpelisib (Piqray®)?, from 2023-01-01 to 2024-12-30
  • L’AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1, from 2021-10-01 to 2026-09-30
  • Pharmacological optimization of OpKemo, a silica-based nanoparticle platform for oncology, from 2022-01-31 to 2024-12-31

Recently finished projects

  • Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site, from 2016-04-01 to 2023-03-31
  • Computational design, synthesis, and screening of FUT8 inhibitors as new anticancer agents_Fortin, from 2022-09-01 to 2023-08-31
  • Design and synthesis of FUT8 inhibitors as new anticancer agents - Fortin, from 2022-04-01 to 2023-07-31
  • Les phénylureidobenzènesulfonates, une nouvelle thérapie de différenciation pour le traitement de la leucémie myéloïde aiguë : preuve de concept, from 2020-02-01 to 2024-01-31
  • Projet parent « Design and synthesis of FUT8 inhibitors as new anticancer agents, from 2022-04-01 to 2023-07-31
  • Soutien séjour en France - 8 au 18 mars 2024, from 2023-10-01 to 2024-04-30
Data provided by the Université Laval research projects registery